New combo therapy targets advanced tumors in early trial
NCT ID NCT00600496
First seen Nov 14, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests a new drug called AZD6244 given with standard chemotherapy for people with advanced solid tumors (like breast, colon, lung, melanoma, or kidney cancer) that have no curative options. The main goal is to see if the combination is safe and tolerable, and to find the best dose. About 140 participants will take AZD6244 pills twice daily alongside their chemo, and researchers will monitor side effects and how the drugs move through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.